(RTTNews) - Predictive Oncology Inc. (POAI), an AI-driven drug discovery company, on Thursday announced plans to launch its flagship ChemoFx drug response assay in Europe, initially focusing on ovarian and other gynecological cancers.
The assay will also be expanded in the United States.
ChemoFx is a live cell treatment selection marker and tumor profiling assay designed to quantify a cancer patient's in vitro response to various chemotherapies.
This approach helps determine which chemotherapy agents are more likely to be effective for individual patients, improving personalized treatment decisions.
The launch is part of Predictive Oncology's strategy to advance clinical trials and standard testing for clinicians treating gynecological cancer patients.
The company has a biobank with approximately 150,000 live tumor samples, nearly half of which are gynecological cancers, with a focus on ovarian cancer.
Raymond Vennare, CEO of Predictive Oncology, said, "ChemoFx represents a crucial asset for personalized cancer care and the development of AI-driven decision support tools in oncology. We expect this initiative to generate significant short-term revenue and long-term growth."
The company's AI-driven platform has been scientifically validated to predict tumor responses with 92% accuracy, further enhancing its potential to support drug discovery and clinical decision-making in cancer treatment.
Currently, POAI is trading at $1.23 up 3.49%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
